Elan's Response to FASB
Executive SummaryWhile the Federal Accounting Standards Board has basically ruled out the kinds of limited partnerships Elan for years used to finance its R&D off its income statement, a new set of deals show just how Elan is using deals with biotechs and other drug delivery companies to both supplement its research program and spare its P&L.
You may also be interested in...
Increasing savvy around cybersecurity issues is driving regulators and trade groups to update their approach to the area, speakers from the US FDA and the American Medical Association said at this week’s FDA/CMS Summit.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.